BACKGROUND: FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. METHODS: We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival, resection rate, R0 resection rate, and grade III-IV adverse events. Patient-level survival outcomes were obtained from authors of the included studies and analyzed using the Kaplan-Meier method. RESULTS: We included 24 studies (8 prospective, 16 retrospective), comprising 313 (38.1%) BRPC patients treated with FOLFIRINOX. Most studies (n = 20) presented intention-to-treat results. The median number of administered neoadjuvant FOLFIRINOX cycles ranged from 4 to 9. The resection rate was 67.8% (95% confidence interval [CI] = 60.1% to 74.6%), and the R0-resection rate was 83.9% (95% CI = 76.8% to 89.1%). The median OS varied from 11.0 to 34.2 months across studies. Patient-level survival data were obtained for 20 studies representing 283 BRPC patients. The patient-level median OS was 22.2 months (95% CI = 18.8 to 25.6 months), and patient-level median progression-free survival was 18.0 months (95% CI = 14.5 to 21.5 months). Pooled event rates for grade III-IV adverse events were highest for neutropenia (17.5 per 100 patients, 95% CI = 10.3% to 28.3%), diarrhea (11.1 per 100 patients, 95% CI = 8.6 to 14.3), and fatigue (10.8 per 100 patients, 95% CI = 8.1 to 14.2). No deaths were attributed to FOLFIRINOX. CONCLUSIONS: This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate. These results need to be assessed in a randomized trial.
BACKGROUND:FOLFIRINOX is a standard treatment for metastatic pancreatic cancerpatients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. METHODS: We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival, resection rate, R0 resection rate, and grade III-IV adverse events. Patient-level survival outcomes were obtained from authors of the included studies and analyzed using the Kaplan-Meier method. RESULTS: We included 24 studies (8 prospective, 16 retrospective), comprising 313 (38.1%) BRPC patients treated with FOLFIRINOX. Most studies (n = 20) presented intention-to-treat results. The median number of administered neoadjuvant FOLFIRINOX cycles ranged from 4 to 9. The resection rate was 67.8% (95% confidence interval [CI] = 60.1% to 74.6%), and the R0-resection rate was 83.9% (95% CI = 76.8% to 89.1%). The median OS varied from 11.0 to 34.2 months across studies. Patient-level survival data were obtained for 20 studies representing 283 BRPC patients. The patient-level median OS was 22.2 months (95% CI = 18.8 to 25.6 months), and patient-level median progression-free survival was 18.0 months (95% CI = 14.5 to 21.5 months). Pooled event rates for grade III-IV adverse events were highest for neutropenia (17.5 per 100 patients, 95% CI = 10.3% to 28.3%), diarrhea (11.1 per 100 patients, 95% CI = 8.6 to 14.3), and fatigue (10.8 per 100 patients, 95% CI = 8.1 to 14.2). No deaths were attributed to FOLFIRINOX. CONCLUSIONS: This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate. These results need to be assessed in a randomized trial.
Authors: Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan Journal: Ann Surg Oncol Date: 2009-04-24 Impact factor: 5.344
Authors: Walid L Shaib; Natalyn Hawk; Richard J Cassidy; Zhengjia Chen; Chao Zhang; Edith Brutcher; David Kooby; Shishir K Maithel; Juan M Sarmiento; Jerome Landry; Bassel F El-Rayes Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-24 Impact factor: 7.038
Authors: Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2017-08 Impact factor: 11.908
Authors: Theodoros Michelakos; Ilaria Pergolini; Carlos Fernández-Del Castillo; Kim C Honselmann; Lei Cai; Vikram Deshpande; Jennifer Y Wo; David P Ryan; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Janet E Murphy; Ryan D Nipp; Aparna Parikh; Motaz Qadan; Andrew L Warshaw; Theodore S Hong; Keith D Lillemoe; Cristina R Ferrone Journal: Ann Surg Date: 2019-04 Impact factor: 12.969
Authors: M Itchins; J Arena; C B Nahm; J Rabindran; S Kim; E Gibbs; S Bergamin; T C Chua; A J Gill; R Maher; C Diakos; M Wong; A Mittal; G Hruby; A Kneebone; N Pavlakis; J Samra; S Clarke Journal: Eur J Surg Oncol Date: 2017-06-28 Impact factor: 4.424
Authors: Jantien A Vogel; Steffi J Rombouts; Thijs de Rooij; Otto M van Delden; Marcel G Dijkgraaf; Thomas M van Gulik; Jeanin E van Hooft; Hanneke W van Laarhoven; Robert C Martin; Annuska Schoorlemmer; Johanna W Wilmink; Krijn P van Lienden; Olivier R Busch; Marc G Besselink Journal: Ann Surg Oncol Date: 2017-05-30 Impact factor: 5.344
Authors: Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff Journal: PLoS Med Date: 2010-04-20 Impact factor: 11.069
Authors: E Versteijne; J A Vogel; M G Besselink; O R C Busch; J W Wilmink; J G Daams; C H J van Eijck; B Groot Koerkamp; C R N Rasch; G van Tienhoven Journal: Br J Surg Date: 2018-04-30 Impact factor: 6.939
Authors: Ammar A Javed; Ding Ding; Erum Baig; Michael J Wright; Jonathan A Teinor; Daniyal Mansoor; Elizabeth Thompson; Ralph H Hruban; Amol Narang; William R Burns; Richard A Burkhart; Kelly Lafaro; Matthew J Weiss; John L Cameron; Christopher L Wolfgang; Jin He Journal: World J Surg Date: 2022-01-07 Impact factor: 3.352
Authors: Shane S Neibart; Swati Mamidanna; Anupama Chundury; Mutlay Sayan; H Richard Alexander; David A August; Lyudmyla D Berim; Patrick M Boland; Miral S Grandhi; Prateek Gulhati; Howard S Hochster; Russell C Langan; Kristen R Spencer; Timothy J Kennedy; Matthew P Deek; Salma K Jabbour Journal: J Gastrointest Oncol Date: 2021-12